RxDoctor Payments Data

Christopher Brian, MD

Cardiovascular Disease · Birmingham, ALNPI 1982789335

Payments from drug & device makers

$3,168in general payments, 2019–2025

Across 194 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$701
  • Pfizer$500
  • Amgen$330
  • Sanofi-aventis U.S. LLC$287
  • Boehringer Ingelheim$242
  • Merck$193
  • plus $915 from 16 others

What the payments were for

  • Food & beverage$3,168100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,168 in reported general payments places this provider in the 50th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$390,962
Medicare patients
838
Services billed
5,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban602$490,260
XareltoRivaroxaban105$108,251
Repatha SureclickEvolocumab103$67,819
JardianceEmpagliflozin83$55,672
MultaqDronedarone Hcl50$52,099
Ranolazine ErRanolazine194$17,877
BrilintaTicagrelor24$17,242
MounjaroTirzepatide11$11,443
Metoprolol Succinate621$10,532
EntrestoSacubitril/Valsartan15$9,736
FarxigaDapagliflozin Propanediol14$8,799
Atorvastatin Calcium491$8,403
Dabigatran EtexilateDabigatran Etexilate Mesylate32$7,383
Praluent PenAlirocumab13$6,458
Flecainide Acetate77$5,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$500$490,260602 claims
Johnson & JohnsonXarelto$116$108,251105 claims
Boehringer IngelheimJardiance$242$55,67283 claims
Sanofi-aventis U.S. LLCMultaq$287$52,09950 claims
AstraZenecaBrilinta, Farxiga$122$26,04238 claims
NovartisEntresto$701$9,73615 claims
Kowa Pharmaceuticals America, Inc.Livalo$24$3,59812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →